Table 1

Comparison of the demographics and management of patients with non-alcoholic fatty liver disease (NAFLD) attending gastroenterology, hepatology and a specialist NAFLD clinic

DomainClinicTotal (%)p value
Gastroenterology (%) n=68Hepatology
(%) n=59
NAFLD clinic (%)
n=20
Patient characteristics
 Sex (% male)30 (44%)32 (54%)7 (35%)69 (47%)
 Diabetes %34 (50%)31 (52%)13 (65%)78 (53%)
 Obesity (BMI >30 kg/m2)35 (52%)43 (73%)17 (85%)95 (65%)
 Cirrhosis %27 (40%)24 (41%)6 (30%)57 (39%)
 Liver biopsy undertaken19 (28%)26 (44%)12 (60%)57 (39%)
Interventions
Alcohol use documented*57 (85%)54 (92%)20 (100%)131 (90%)0.121
Liver imaging (Ultrasound scan)*64 (96%)58 (98%)20 (100%)142 (97%)0.519
Non-invasive staging*39 (57%)40 (68%)20 (100%)99 (67%)0.001
Staging within 3 years*29 (45%)36 (67%)17 (85%)82 (59%)0.003
Blood pressure checked*38 (56%)36 (61%)20 (100%)94 (65%)0.001
Lipids tested*43 (64%)38 (64%)20 (100%)101 (69%)0.005
Blood sugar addressed54 (79%)40 (68%)20 (100%)114 (78%)0.004
BMI documented at review appointment*47 (70%)35 (60%)4 (20%)‡86 (59%)<0.001
Waist circumference documented0 (0%)1 (2%)20 (100%)21 (14%)<0.001
Weight loss advice documented46 (68%)51 (86%)19 (95%)116 (79%)0.006
 Documented advice to lose ≥10% body weight†6 (9%)4 (7%)5 (25%)15 (10%)0.084
Statin prescribed*35 (56%)31 (61%)16 (80%)82 (61%)0.153
Referred to structured lifestyle programme6 (9%)4 (7%)11 (55%)21 (15%)<0.001
  • *Pearson χ2 test was used.

  • †Fisher’s exact test was used.

  • ‡Although body mass index (BMI) not formally documented, height and weight were documented for all patients.